The goal of this clinical trial is to test the safety and efficacy of a medical device in subjects with cerumen in excess. The main questions it aims to answer are:

• Does the medical device induce skin irritation in the ear canal?
• Does the medical device reduce obstruction of ear canal induced by excessive cerumen?

Participants will use the device in each ear, once a day, every 3 days at home. Researchers will compare the medical device group to a control group who will not use the medical device.

Ocean Bio Actif Hygiène de l'oreille is a medical device class IIa indicated for the prevention of the formation of earwax plugs and consequently the pathologies linked to the accumulation of earwax (hearing loss and infection/affection of the external auditory canal).

This clinical investigation is designed to improve the quality and quantity of data available on both the safety and the efficacy of Ocean Bio-Actif, in order to confirm the safety and the efficacy of the product in a post-market environment.

The objective of the current clinical investigation is to confirm the efficacy and safety of topical application to the ear canal of Ocean Bio-Actif.

Inclusion Criteria:

• Gender: female and/or male.

• Age:

  30 to 40% having age between 3 to 12 yo, 30 to 40% between 13 to 65 yo, 30 to 40% more than 65 yo.

• Subjects able to use the tested product.

• Subjects having history of cerumen occlusion more than once a year with or without symptoms (reduction of hearing function, obstruction feeling of the ear canal,..).

• Subjects having ear help system or regular users of systems such as anti-noise plugs or headsets (only for the 13yo subjects and more).

• Subjects having a clinical score of ear canal obstruction of 2 or 3 at D0.

Exclusion Criteria:

• Subjects who had chirurgical act on the mastoïde.
• Subjects who had severe troubles of the internal ear (severe dizziness, desorientation, nausea).
• Subjects using regularly a ear spray for washing his/her ears.
• Subjects having a score of ear canal obstruction at 4 at D0.
• Pregnant or nursing woman or planning a pregnancy during the study;
• Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship;
• Subject in a social or sanitary establishment;
• Subject suspected to be non-compliant according to the investigator's judgment;
• Subject with a condition or receiving a medication which, in the investigator's judgment, put the subject at undue risk;
• Subject suffering from a severe or progressive disease.

The overall Number of Baseline Participants does not differ from the number of participants assigned to the arm or comparison group and in the entire study population.

90 days

No serious adverse event is expected. No risk for mortality is expected.